The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Potash was a good bet for me and the value of potash increased when fertilisers became short. There was just one tiny tiny problem which was the plant to process the extraction did not work as designed. The big lenders had first call on the considerable infrastructure that has been built (after several placings etc.) so I guess it was a no brainer to them to turn off the financial taps and let the company fail. I have to agree that Australian CEO's seem to have more than their fair share of bad luck shall we say :).
At least here we have products already for sale and we just have to hope for further sales and successful use of the products. I should have learnt some time ago from my experience with gold miners, the only ones who have earnt me a bit of profit are ones that were already producing before I bought in (as opposed to being a hopeful hole in the ground). Mind you I mustn't get too enthusiastic or Ill end up buying some more CREO when I get some 'spare' cash.
cheers 1eyedman
you mean so4 and yeah,think they did some nasty big placings aswell.
potash?...eml..that ones done real well and still going strong,dunno the funding debt situation.
harvest minerals aswell.
neither have australian ceo's.lol.
Troajan
Yes it’s odd. Mind you when it was clear that my last AIM investment was going to go under quite a few obvious rampers appeared which pretty disappointing. Another one I had and sold was a miner endlessly waiting for a licence, I did not post on that board but sometimes check in and the same people are there years later still waiting for the licence. Very civilised around here though!.
Gl yourself
1eyedman
i see it all over,some great comps and no one posts,on them.
then you get other comps,dodgy as heck and the boards,overflowing.
odd that.lol.
gl
“A very busy board” :). It’s quality that counts.
Appreciate the links though.
https://www.proactiveinvestors.co.uk/companies/news/1013470/creo-medical-powers-on-towards-profitability-1013470.html
a very busy boatd this.
Agreed, positive forward looking RNS. For balance though the elephant in the room is the yearly loss. This will need to turn round pretty fast to avoid further dilution. No deal breakers though which is a good start!.
GL
Good rns and things sound upbeat and positive , looking forward to seeing how things progress
Good luck all
John
Interesting and informative RNS. It may not have much immediate effect on SP as the studies look pretty long term which I guess is to be expected. It would be excellent if the device proves to be effective for issues not currently eligible for surgery (from RNS). From a human perspective I mean in this instance. What a useful tech this could turn out to be.
I wonder if enthusiasm for this news will reinflate the price?
'A surprise either way would have a dramatic impact on the sp.'
Also totally agree with this. I feel it is a positive to have the product already and the race to profit depends on driving sales and training. Things can go very wrong or right depending on whether milestones are met. The company still has a fairly decent market cap though, the real worry comes when a company is worth buttons but still needs to raise. Which CREO clearly doesn't unless they splash cash on a an acquisition.
Agree. Critical that they demonstrate strong sales growth for core products. A surprise either way would have a dramatic impact on the sp.
@ Theorist. Well had I put my shirt on SO4 I would be half naked now which is not a good thought!. I actually thought they might get potash process over the line but in keeping with many AIM stocks ran out of money and the well of share issues had run dry. Still that is history and I’m back in the fun zone.. Would not have bought in to CREO if the story did not make some sense. I tend to use these boards occasionally but not as an investment aid. If you have seen my SO4 posts hopefully it’s pretty clear that although I like to be positive (otherwise why buy the share) I don’t have blind faith when the writing is on the wall that a company is falling over. Hopefully not something we will experience in this case :).
1eye, whatever you lost on SO4 you will make it back on Creo. The circumstances that crashed Creo’s sp were unusual and have given an incredible opportunity to people like you. If you take the time to read what the Creo instruments can do, maybe start with the most recent publications, annual report, it is amazing. Han**** is an absolute genius. Of that there is no doubt.
I decided to burden this share with a small investment after becoming interested on the back of a MF article. Buying after a successful placing seemed as good a time as any in the hope there wont be another one for a while!. This seems like another race to profit before running out of money (sorry to state the obvious!) but I do like a gamble.
Good luck to us!
It’s certainly a thought. What could be the potential damage to CMR or Intuitive if they were shut out of the Creo technology? Does the suite of Creo products genuinely provide a significant competitive advantage? Creo has been around a while now, both CMR and Intuitive must have taken a very close look but not much has happened. Plus the valuation of Creo is so, so low yet that hasn’t attracted their attention. $20m would give either CMR or Intuitive a blocking stake in Creo, so even if they didn’t want to acquire it at least they could stop their competitor from having a free run at it. Or do they see the robotic market as so vast that they don’t care? I certainly don’t have the knowledge to be able to answer any of these questions but it is certainly intriguing.
"wedded"? Not much of a marriage if they are cheating with another company. CMR surely have a huge incentive to bid IF the tools offer an advantage, it's an obvious way to target market share, which is surely their main objective? To dismiss it out of hand seems illogical
CMR has less than 5% of the market plus Creo is already wedded to Intuitive. So no bidding war. The hope some time back was that either Olympus or J & J would have a tilt at Creo.
That's an interesting thought Theorist, and you can see the temptation for either Intuitive or CMR to buy them out and gain an advantage over the other, if they offer a significant enough advantage. They are kind of in an arms race now to integrate the tools with their systems, it could conceivably lead to a bidding war, but I wouldn't bank on it. Robotic "arms", of course ( :
BBD 100% agree with your observations. Obviously if the Intuitive business takes off the break even point could come forward. I asked the directors very recently if there were any emerging threats to the Creo technology and they were adamant there is nothing whatsoever out there or in the pipeline. To me this is absolutely crucial because there is no doubt at all that the Creo instruments are at the leading edge. This company will reach its destination. The rewards for shareholders will come, it’s just timing. I was surprised that Intuitive hasn’t taken the opportunity to buy Creo for nothing but many companies like Intuitive have a fairly rigid business model and resist temptations to diversify. Hopefully over the coming months we will see Intuitive really rubber stamp the Creo technologies and effectively eliminate any doubt about the company’s prospects.
Turning a profit is years away, and an elusive moving target. Some analysts estimate 3 years, but that's a recent revision from late 2025, and I'd guess a later date rather than an earlier one, based on what generally happens - hype tends towards the positive rather than the realistic. Having said that, the products continue to look world leading, indeed world changing, and deals with both leading robotic surgery companies supports that. If the post Covid boom can be sustained, the recent acceleration in uptake might go into overdrive. Logistically, CREO now seems well set up to facilitate that. Fingers crossed (unless you're a surgeon)
Agree, £2.1m is a significant sum. The directors are very confident that they can make this work, couple this with Intuitive I think at 25p or so this is an extraordinary opportunity.